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DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

Abstract
Advances in technology and transparency have greatly accelerated the ability of clinicians to
remain current with regards to being informed and informing patients about the risk/benefit ratio
when considering antidepressant medication. In spite of this, the current climate of
pharmaceutical industry influence on medical practice does much to hinder informed consent
processes. Recent findings of previously unknown and potentially dangerous adverse effects of
the second- and third-generation classes of antidepressants underscore the importance of
enhancing the practice of informed consent. After considering the concept of informed consent
as it has evolved over time, the authors summarize some of the newer side effects associated
with second- and third-generation antidepressants and then move on to describe impediments in
the way of achieving adequate informed consent at the clinical encounter. Among these
impediments, the authors discuss the impact of industry influence, cognitive bias in decisionmaking, and time constraints. These obstacles and the notion that modern antidepressants are not
as safe as once thought offer an opportunity to revisit the process of informed consent. A
dynamic concept of informed consent is proposed with the acknowledgement that a mere listing
of side effects or pro forma approach to informed consent is inadequate, and that a deep and
ongoing conversation with patients will more likely result in patient empowerment and a
strengthening of the therapeutic alliance. This process is analogized to an “n=1” approach where
patients’ idiosyncratic responses to second- and third-generation antidepressants can be used to
update prior beliefs based on large-scale trials and allow patient and doctor to shoulder the
burden of uncertainty together, thereby enhancing placebo and minimizing nocebo response and
leading to more optimal treatment outcomes.
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Introduction
Over the last few decades, evidence-based approaches to the management of psychiatric
disorders have incorporated the concept of concordance or shared decision-making between
clinicians and patients (Appelbaum & Grisso, 1997; Deegan & Drake, 2006; Penston, 2007). As
a result the paradigm has shifted from a paternalistic model, where the clinician makes decisions
for patients, to a patient-choice model. However, the prevalence of academic-industry
collaborations, the dramatic increase in industry-funded research, the financial ties between
prescribing providers, organized medicine, and the pharmaceutical industry, and the rise of
psychopharmacology as the predominant intervention in psychiatry have complicated, and in
some ways compromised, the informed consent process. For example, there is evidence of
attempts by some pharmaceutical companies to influence vital information regarding efficacy
and safety studies in high ranking medical journals through practices such as ghost writing and
selective reporting of clinical trials and outcomes. In addition, there is documented variability in
the reporting of harm-related results in publications of randomized controlled trials (Howland,
2011; Pitrou, Boutron, Ahmed, & Ravaud, 2010; Spielmans & Parry, 2010). Despite these
clearly unethical practices, the problem most often “is not venality or intentional deception….
The problem is that bias can so easily be introduced unintentionally” (Avorn & Choudhry, 2010,
p. 2233). As a result, the published literature may not fully capture a balanced view of the
risk/benefit ratio for commonly prescribed psychotropic medications such as antidepressants.
The fact that clinicians may be receiving imbalanced and perhaps inaccurate or biased
information about the side effect profiles of newer antidepressants is particularly problematic in
light of the rise in antidepressant use. A recent Center for Disease Control report announced that
there has been a 400% increase in the use of antidepressants since 1988; currently over twenty-
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seven million people in the United States are taking antidepressants. In addition to being the
standard treatment for depressive disorders, antidepressants are increasingly being prescribed for
other conditions such as chronic daily headache, back pain, neuropathy, sleep-related conditions,
fatigue, anxiety spectrum disorders (e.g., social anxiety disorder and panic disorder), adjustment
disorders, eating disorders, fibromyalgia, and hot flashes. This widening range of use may be
driven in part by the longstanding perception that modern antidepressants are extremely safe.
However, recent research has shed a more sobering light on the actual safety and tolerability
profiles of second- and third-generation antidepressants. Policy makers, bioethicists, and health
care professionals are thus in full agreement that providers need to “integrate information about
medical risks of serotonergic antidepressants into their clinical decision-making, informed
consent process, baseline assessment, and follow-up monitoring” (Looper, 2007: 7; see also
Bahrick & Harris, 2008).
Despite the concern that these data have generated, however, it seems that clinical
practice has yet to adapt. A recent study demonstrated that in only 1.5% to 2% of clinical
sessions did psychiatrists discuss the issue of adverse effects with their patients after initiating
treatment with an antidepressant (Linden & Westram, 2011). Moreover, informed consent is
hardly mentioned in the American Psychiatric Association's clinical practice guidelines for the
treatment of Major Depressive Disorder (American Psychiatric Association, 2010).
The recent discoveries of new and potentially dangerous adverse effects of
antidepressants, along with the compromised state of informed consent practice, warrant a
reappraisal of the informed consent process regarding these common medications. In this article,
after considering the concept of informed consent as it has evolved over time, the authors review
the adverse effects associated with second- and third-generation antidepressants and then move
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on to discuss various impediments to the informed consent process, such as the influence of the
pharmaceutical industry on the information available to prescribers and its quality, cognitive
biases in decision making, and the widespread conceptualization of informed consent as a single
action. The authors conclude by reframing informed consent as a dynamic rather than a pro
forma process that involves approaching antidepressant prescription empirically and
collaboratively, allowing doctor and patient to manage uncertainty together within the treatment
alliance and leading to more optimal treatment outcomes.
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Informed consent: A brief history and context
As Beauchamp (2011) noted, although the term ‘informed consent’ emerged in the 1950s,
serious discussion about the meaning of informed consent, particularly in terms of the patient’s
or research participant’s perspective (i.e., his/her actual understanding of the information being
disclosed), did not receive serious attention until the 1970s. The concept of informed consent as
it applies to research was first formally defined by the Nuremberg Code in 1947 and continued to
be updated over time by various organizations, including the World Medical Association in
Helsinki in 2004 (http://ohsr.od.nih.gov/guidelines/helsinki.html). Over time the concept of
informed consent in clinical practice evolved as well and came to signify “the disclosure of
important information so that a patient may be able to assess the risks and benefits of the
proposed treatments and understand the alternatives to the proposed treatment” (see e.g.,
Bursztajn, Feinbloom, Hamm, & Brodsky, 1990; Gutheil, Bursztajn, & Brodsky, 1984).
Although there are different standards for disclosure, such as the professional practice
standard, which focuses on the question of the customary practices of the profession, it is the
reasonable patient standard that is used most frequently in the United States as the required
threshold for disclosure. This standard, derived from the landmark Canterbury v. Spence federal
court ruling, can be stated as following: “What would a reasonable patient want to know with
respect to the proposed therapy and the dangers that may be inherently or potentially involved”1
(464 F.2d 772, 1972). A risk is considered material when a reasonable person, in what the
physician knows or should know to be the patient's position, would be likely to attach a
significance to the risk or cluster of risks in deciding whether or not to forego the proposed

1

Canterbury v. Spence, 464 F.2d 772, 1972.

5

DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

therapy2,3 (Cantebury v. Spence, 464; Foy v. Greenblott, 141 Cal. App. 3d. 1, 9, 1983; Mathis v.
Morrissey, 11 Cal. App. 4th 332 [13 Cal. Rptr. 2d 819], 1992). In 2003, a review (Mazur) noted
that the reasonable patient standard for informed consent was gaining currency not only in the
United States but also internationally, in Canada, Great Britain, and Australia. This trend has
continued to date and given the globalization of clinical trials is likely to continue. Moreover,
given the adoption and usage of a variety of “universal” human subject protection codes on the
heels of the Nuremberg trials, the international influence of the reasonable patient standard for
informed consent is likely to grow.
Despite these major legal rulings, the emergence of an entire field of bioethics, and the
proliferation of literature on the topic of informed consent, the practice of making sure that one
obtains meaningful informed consent “has been slow to conform to abstract theory”
(Beauchamp, 2011, p.517). Moreover, the concept of informed consent was developed when
medical information was far more static and trust in biomedicine and regulatory bodies was
taken for granted. The framers of informed consent practices could not have anticipated an
information age in which advances in technology allow immediate and public access to emerging
data regarding drug efficacy and side effects. Nor could they have anticipated the prevalence of
collaborations between academic organizations and the pharmaceutical industry—collaborations
that have raised real questions about how meaningful the informed consent process can be if
practitioners are not privy to accurate and complete data on efficacy and risks of medications.

2

Foy v. Greenblott, 141 Cal. App. 3d. 1, 9, 1983.

3

Mathis v. Morrissey, 11 Cal. App. 4th 332 [13 Cal. Rptr. 2d 819], 1992.
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In order to respect patient autonomy, the informed consent process must begin with
physicians who have a clear understanding of the risks and benefits inherent in prescribing a
medication as well as how various alternatives fare in comparison. In today's industry-dominated
climate, marketing and publishing tactics utilized by drug companies make it difficult for the
prescriber to be adequately informed. Indeed, the field of medicine has had to contend with some
glaring examples of iatrogenic harm caused by the distortion of important information about a
drug’s adverse effects. Merck’s blockbuster drug Vioxx (Rofecoxib), which nearly doubled the
risk of myocardial infarction and stroke (Bresalier et al., 2005; Avorn & Choudhry, 2010), is
perhaps the most well-known case. As a result of this and other high profile cases, providing
genuine informed consent has become a critical public health issue for all medical subspecialties.
We therefore proceed with a survey of some of the known adverse effects of the second- and
third-generation antidepressants.
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Side effects and adverse events
Post-market monitoring of second- and third-generation antidepressants has called into
question the perception that they are mostly safe. Recent meta-analyses and reviews of safety
and tolerability information of clinical trials provide the bulk of data underlying this concern (see
Table 1: Summary of side effects and adverse events associated with second- and thirdgeneration antidepressants). For example, in an updated meta-analysis, Gartlehner et al. (2011)
found that 63% of patients reported at least one adverse event during the course of treatment and
that discontinuation rates between selective serotonin reuptake inhibitors (SSRIs) and other
second-generation antidepressants were generally similar. Of note is that due to the size and
length of most trials, the authors conclude that comparative risk across drugs for serious adverse
events other than sexual dysfunction (i.e., suicidality, cardiovascular events, hyponatremia,
seizures, hepatotoxicity, and serotonin syndrome) could not be determined. Since such clinical
trials cannot sufficiently capture the less common but more serious adverse events, the United
States Food and Drug Administration (FDA) depends on post-market surveillance in order to
detect and respond to these events (Wolfe, 2012).
One serious adverse event that does appear in clinical trials is sexual side effects.
Montejo-Gonzalez et al. (1997) found that over 50% of subjects taking an SSRI experienced
some type of sexual dysfunction, with decreased libido and delayed orgasm being the most
common. Clayton, Keller, and McGarvey (2006) note that even for patients who do not qualify
for global sexual dysfunction, 96% of female patients and 98% of male patients taking SSRIs
experience dysfunction in at least one sexual phase. Seidman (2006) noted that at least 25% of
men taking SSRIs experience delayed ejaculation. This phenomenon is likely underreported, as
the correlation between SSRIs and delayed ejaculation in men is not well-researched.

8

DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

Other SSRI side effects continue to be discovered. Recent reports suggest that SSRIs
increase the risk of upper gastrointestinal (GI) tract bleeding (Dalton, Sørenson, & Johansen,
2006; de Abajo, Montero, Rodriguez, & Madurga, 2008; Loke, Trivedi, & Singh, 2007) and pose
particular problems for the elderly, including increased risk for falls, bone fractures (Hermann
2000; Richards et al., 2007), and hyponatremia (Movig, 2002), and a possible effect on
intraocular pressure for those at risk for glaucoma (Costagliola, Parmeggiani, & Sebastiani,
2004). Ziere et al. (2008) found that SSRI use more than doubles the risk of nonvertebral
fracture, with the risk increasing in those taking an SSRI for more than six months. Weight gain
associated with SSRI use (Fava, 2000) has led to concerns about increased diabetes risk with
long-term use (Andersohn, Schade, Suisse, & Garbe, 2009). Haddad and Dursun (2008) also note
the increased risk of serotonin toxicity and discontinuation syndrome in patients treated with
SSRIs. Rarely, suicidality is also associated with antidepressant use (Reeves & Ladner, 2010),
with some evidence of increased risk with SSRIs relative to tricyclic antidepressants (TCAs)
(Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005).
In addition, studies have documented adverse neonatal outcomes in relation to maternal
exposure to SSRIs and other newer serotonergic/noradrenergic antidepressants from the last
trimester through delivery, including mild central nervous system, motor, respiratory, and GI
signs and metabolic dysfunction (see Tuccori et al., 2009 for review) as well as cardiovascular
defects (Diav-Citrin et al., 2008; Louik, Lin, Werler, Hernandex-Diaz, & Mitchell, 2007) and a
risk of persistent pulmonary hypertension (Chambers et al., 2006).
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Progress in the field of pharmacodynamics has led to increasing concerns about the
complex relationships among serotonin, SSRIs, certain TCAs, prolactin, and tamoxifen, and how
these inter-relationships affect both pharmacodynamics and cancer risk (Kelly et al.,
2010). Some antidepressants, especially SSRIs, are potent inhibitors of the cytochrome P450
monooxygenase enzymatic system (a system that metabolizes antineoplastic as well as
other agents). Thus, antidepressants may directly enhance tumor cell proliferation as suggested
by the expanding biological and clinical research on cytochrome P450 enzymes and
the deleterious effects of these enzymes on the metabolism and therapeutic efficacy of tamoxifen
and other antineoplastic agents (Spina et al., 2008; Aubert et al., 2009). In fact, researchers
found an increased risk of death from breast cancer in 630 women taking paroxetine while
receiving tamoxifen therapy (Kelly et al., 2010). Moreover, women treated with tamoxifen who
were also treated with a moderate to potent cytochrome P2D6 inhibitor (fluoxetine, paroxetine,
or sertraline) were found to have an increased risk of a breast cancer recurrence compared to
women taking no SSRI (Aubert et al., 2009), although it should be said that in another study
researchers did not observe an elevated risk of breast cancer recurrence in women treated with
antidepressant inhibitors of cytochrome P2D6 (Azoulay, Dell’Aniello, Huiart, Galbaud du Fort,
& Suissa, 2011).
In sum, although the more recent findings regarding adverse events are preliminary, they
raise significant questions about the safety and tolerability of second- and third-generation
antidepressants and prompt a revisiting of the informed consent process for this class of drugs.
Drugs once considered to be safe and tolerable, with sexual dysfunction and GI discomfort
thought to be their primary adverse effects, are now suspected to carry serious risks such as
gastrointestinal bleeding and an increased risk of fractures. This problematic situation is further
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complicated by marketing practices distorted by financial conflicts of interest and places a heavy
burden of responsibility on clinicians to avoid pitfalls and manage uncertainties within the
process of informed consent so that patient autonomy will not be compromised.
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Communicating the emerging data on side effects: Toward a more genuine informed
consent process

Industry plays a dominating role in psychopharmacological education (Brodkey, 2005;
Gagnon & Lexchin, 2008), and there is increasing documentation that the evidence base gets
distorted as a result of these partnerships (Friedman & Richter, 2004). It is noteworthy that the
financing for educational/promotional activities of pharmaceutical companies are derived from
their marketing and administrative budgets (Brodkey, 2005). It is therefore important for
prescribers to be mindful of pharmaceutical marketing strategies and to actively seek information
from independent sources (e.g., the Cochrane Central Register of Controlled Trials and
MedWatch, the FDA website for updated reporting of safety information and adverse events)
rather than relying on updates regarding the risks and benefits of any given medication from an
industry-sponsored source (Applbaum 2009; Shaughnessy, Slawson, & Bennett, 1994;
Spielmans & Parry, 2010).

Semantic decision-making biases often combine with marketing strategies to form
another potential pitfall on the way to genuine informed consent (Bursztajn et al., 1991;
Bursztajn, Chanowitz, Gutheil, & Hamm, 1992). For example, warnings and contraindications
buried in the “adverse events” section of the labeling of a pharmaceutical product are not likely
to be remembered as well as the indications and benefits that are prominently promoted.
Moreover, the consequences of automated thinking (Hamm, 2009b) and the “irrational
persistence in belief” (Hamm, 2009a) may be reinforced by delays in disclosing adverse effects
of medications. Many clinicians have internalized the belief that second- or third-generation

12

DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

antidepressants are always the treatment of choice. Once such automatic prescribing habits set in
they become difficult to dislodge. Additionally, industry promotion can subtly—but
powerfully—frame the questions clinicians ask. For example, the “newer is better” bias
encourages questions such as “Which among this new class of drugs is better than the others?”
rather than "How are these new drugs any better than older drugs or alternative treatments?"

In order to facilitate collaborative decision-making, it is important for clinicians not only
to review independent sources of information for emerging safety and efficacy data, but also to
initiate conversations with their patients about these new data. It is helpful to communicate to
patients that it is indeed difficult to make sense of all of the information they hear and read about
regarding their psychotropic medications (e.g., in direct-to-consumer advertising campaigns,
news stories, etc.). Evidence suggests that prescribing physicians vary in their beliefs about what
constitutes an adequate level of knowledge disseminated to patients about relative benefits and
harms of treatments (Larkin, Clifton, & de Visser, 2009; Laugharne, Davies, Arcelus, &
Bouman, 2004). Instead of adopting a “don’t ask, don’t tell” policy, it is recommended that
clinicians specifically invite patients to voice any and all concerns about a medication’s side
effects or lack of effectiveness (Cosgrove & Bursztajn 2007). The clinician who is proactive and
takes care to inform patients during the course of treatment about newly emerging data is more
likely to enhance a trusting relationship and therapeutic alliance than one who avoids difficult
dialogues.
Emerging evidence on antidepressant side effects and efficacy also invite a shift in
attitude regarding the prescription of antidepressants from standardized to empirical. There is an
argument to be made that updated data on the variable efficacy of antidepressants in treating
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mild to moderate depression (Fournier et al., 2010) have transformed American Psychiatric
Association guidelines recommending standard treatment into an investigative process for each
individual patient. With increasing applicability of the reasonable person standard as outlined
earlier, this shift would necessitate the tactful updating of patients who previously believed that
their treatment was standard with the information that their treatment is empirical and in effect, a
one-person experiment.

In this spirit, and rather than being bound solely by statistics culled from studies
involving large numbers of subjects, we suggest that clinicians adopt an “n=1” attitude to the
weighing of risks and benefits with patients. Average rates taken from studies will of course
inform our prior probabilities of adverse events and initial conversations with patients, but the
informed consent process is best conceptualized as a collaborative journey where both benefits
and side effects are continually updated for each individual patient. This is particularly important
in light of data suggesting that the presence of mental illness can complicate a patient’s response
to medications and may result in intolerance or even the experience of rare side effects (Davies,
Jackson, Ramsay, & Ghahramani, 2003), and moreover that idiosyncratic reactions to SSRIs
abound, with outcomes from any single medication trial often being unpredictable (Berndt,
Bhattacharjya, Mishol, Arcelus, & Lasky, 2002).

These waters of uncertainty suggest a larger role for the informed consent process itself
as a conduit for treatment. By initiating a conversation with patients that includes not just
frequent psychoeducation and provisions for close monitoring, but also an exploration of
patients’ expectations and the meaning of medications as it relates to their identity and suffering,
physicians may be able both to enhance placebo and minimize nocebo effects that are typical of
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pharmacologic treatment of depression (Fournier et al., 2010). A dynamic approach to informed
consent can do much to distinguish pharmacology from mere pill-dispensing (Gopal,
Pirakitikuir, & Bursztajn, 2005) and presents an opportunity to manage the ambiguity
surrounding psychiatric illness within a healthy therapeutic alliance (Gutheil et al., 1984).
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Conclusion

Clinicians today practice in a time-limited, pharmaceutical-industry dominated climate in
which reductive biological models are heavily promoted. Such models reinforce an acontextual
view of patients’ problems and a disease- rather than patient-centered model of care. As a result,
“diagnosis by checklist” (Andreasen, 2007) becomes a primary source of automatic prescribing
(Cosgrove & Bursztajn, 2007). Thus, genuine informed consent requires, first and foremost, that
mental health professionals adopt a mindful approach to psychiatric taxonomy and be aware not
only of the uses, but also the limitations of and alternatives to psychopharmacological
interventions. Respecting patient autonomy requires that clinicians be aware of the marketing
practices and biases that may distort their appraisal of the relative risks and benefits of
medications such as antidepressants, and moreover that they consider the ways in which people
can be manipulated by social constructions of normalcy and health in an industry-dominated
climate (see e.g., Ells, 2003). This increasingly complex network of considerations presents
distinct challenges for clinicians, but dynamic informed consent processes offer a way to
acknowledge the uncertainty associated with antidepressants while simultaneously empowering
patients in their recovery from illness.
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Table 1: Summary of side effects and adverse events associated with second- and thirdgeneration antidepressants
First Author

Year of

Study Type

Results

Publication
Mentejo-

1997

Gonzalez

Side Effect
Category

Prospective

Over 50% of

cohort study

participants

Sexual

experienced
some sexual
dysfunction.
Sexual
dysfunction
varied across
SSRIs and was
positively
correlated with
dose.
Clayton

2006

Cross-sectional

95.6% of women

observational

and 97.9% of

study

men who do not

Sexual

qualify for global
sexual
dysfunction
experience
sexual
dysfunction in at
least one phase.
Dalton

2006

Review

Evidence for a
causal role of

Gastrointestinal
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SSRIs in upper
GI bleeding
events.
De Abajo

2008

Review

Evidence for

Gastrointestinal

increased risk of
upper GI
bleeding with
SSRI use. Risk is
increased for
elderly and
concomitant use
of NSAIDs.
Loke

2007

Systematic

Use of SSRIs

review

alone and with

Gastrointestinal

NSAIDs
increases the risk
of upper GI
bleeding.
Herrmann

2000

Review

Potential adverse

Special

events of falls,

populations:

hyponatremia,

elderly

weight loss,
sexual
dysfunction, and
drug interactions.
Richards

2007

Prospective

Associated with

Osteo; Special

cohort study

increased risk for

populations:

bone fracture and elderly

27

DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

falls.
Movig

2002

Case-control

Increased risk of

Metabolic;

hyponatremia

special

when compared

populations:

with other

elderly

classes of
antidepressants;
more common in
elderly patients.
Costagliola

2004

Review

Relationship

Special

between SSRI

populations:

use and changes

elderly

in intraocular
pressure,
especially for
elderly.
Ramasubbu

2004

Systematic

Very low rates of

review

cerebrocascular

Cerebrovascular

adverse events
exist, including
intracranial
hemorrhage,
disease, and
vasoconstrictive
stroke.
Ziere

2008

Prospective

Risk of

Special

cohort study

nonvertebral

populations:

fractures with

elderly;
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SSRI use,

musculoskeletal

particularly
prolonged use.
Fava

2000

Review

Use of SSRIs as
a class are
associated with
weight gain.

Andersohn

2009

Case-control

Risk of diabetes

Endocrine

mellitus
increased with
long-term use of
SSRIs and
tricyclic
antidepressants.
Haddad

2008

Review

Risk of serotonin
toxicity,
decreased seizure
threshold, and
neurological
symptoms of
discontinuation
syndrome.

Reeves

2010

Review

Evidence
supports the rare
occurrence on
antidepressantinduced
suicidality.

Neurological
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Fergusson

2005

Systematic

Association

review

between SSRI
use and suicide
attempts when
compared to
placebo and nonTCA
antidepressants.

Gunnell

2005

Meta-analysis

Some evidence
for increased risk
of self-harm and
moderate risk of
suicidal thoughts.

Tuccori

2009

Review

Association

Special

between

populations:

maternal

pregnancy

exposure and
persistent
pulmonary
hypertension and
self-limiting
neonatal
behavior
syndrome in
infant. Possible
increased risk of
miscarriage and
other neonatal
risks require
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further study.
Diav-Citrin

2008

Prospective

Exposure to

Special

cohort study

fluoxetine in first

populations:

trimester

pregnancy

associated with
cardiovascular
anomalies in
newborns.
Louik

2007

Case-control

Some SSRIs may Special

study

increase risk of

populations:

certain

pregnancy

cardiovascular
defects in infants
when used in
first trimester.
Chambers

2006

Case-control

Association

Special

study

between use of

populations:

SSRIs in late

pregnancy

pregnancy and
risk of persistent
pulmonary
hypertension in
the infant.
Kelly

2010

Population-based

Concomitant use

Special

cohort study

of paroxetine and populations:
tamoxifen

breast cancer

association with

patients

increased risk of

31

DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS

death resulting
from breast
cancer.
Spina

2008

Review

Second-

Drug-drug

generation

interactions

antidepressants
differ in their
potential to
interact with
other
medications.
Aubert

2009

Retrospective

Clinically

Special

cohort study

significant

populations:

interaction

breast cancer

between

patients

tamoxifen and
CYP2D6
inhibitors, which
includes some
secondgeneration
antidepressants.
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